![]() |
Open for inclusion |
Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (MK1454-002)Cancer type: Head and Neck cancer Phase: II Principal Investigator: Bratland Åse Country: NO Keywords: Norway, Oslo, Bergen, head and neck, MK1454, pembrolizumab, keytruda Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT04220866 |